BLAINJECTIONINJECTABLEPriority Review
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
8
Mechanism of Action
Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions
Pharmacologic Class:
Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager
Clinical Trials (5)
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Started Dec 2025
18 enrolled
Metastatic Uveal Melanoma
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Started Oct 2025
47 enrolled
HLA-A*0201 Positive Cells PresentClear Cell Sarcoma (CCS)
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Started Aug 2025
44 enrolled
Uveal Melanoma
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Started Feb 2025
30 enrolled
Metastatic Uveal MelanomaMetastatic Uveal Melanoma in the Liver
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Started Nov 2024
290 enrolled
Uveal Melanoma